Premium
Metabolism of BW 1370U87 in rat, dog, and man
Author(s) -
Harrelson Jane Croft,
Johnson Thomas E.,
White Helen L.,
Welch Richard M.
Publication year - 1992
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430250307
Subject(s) - metabolite , metabolism , chemistry , endocrinology , medicine , pharmacokinetics , oral administration , pharmacology , biology
BW 1370U87 is a potent, selective inhibitor of rat and human brain MAO‐A. The plasma concentrations of BW 1370U87 and its metabolites were determined in rat, dog, and man. After an oral dose, BW 1370U87 undergoes extensive first‐pass metabolism in all species studied. The 1‐(1,2, dihydroxyethyl) metabolite, BW 1003U88, was a major metabolite in rat, dog, and human plasma. The 1‐(1‐hydroxyethyl) metabolite, BW 183U88, was a major metabolite in dog plasma, whereas it was present in much lower concentrations in the rat and man. Both BW 1003U88 and BW 183U88 are active MAO‐A inhibitors although not as active as the parent compound. The inactive 1‐(2‐acetic acid) metabolite, BW 1552U88, was a major metabolite in rat plasma but a minor metabolite in the dog. Plasma concentration versus time profiles in both rat and man suggest that the metabolites undergo enterohepatic recycling. Although plasma concentrations of BW 1370U87 were relatively low compared to the metabolites, the concentrations detected in rat and man after a 50 mg/kg or 400 mg oral dose, respectively, exceeded the IC 50 value measured in rat and human brain. Furthermore, the time course of MAO‐A inhibition appears to follow the plasma concentration versus time profile of BW 1370U87 in the rat. Preliminary experiments in rats indicate that BW 1370U87 and its metabolites distribute into brain and inhibit MAO‐A.